[Interaction between anti-aggregating and anticoagulant agents. A double blind study on the concomitant administration of nicergoline and acenocoumarols].
A double blind study was carried out comparing 10-methoxy-1,6-dimethyl-ergoline-8 beta-methanol-(5-bromonicotinate) (nicergoline, Sermion) and placebo in 60 thromboembolic patients on long-term controlled acenocoumarol treatment. Aim of the trial was to assess the hypothesis of an interaction on both the coagulatory parameters and the clinical findings. No significant variations of the acenocoumarol daily dose were required in nicergoline treated group and no interaction was demonstrated in coagulatory parameters. Prothrombin activity and thrombo-test evaluated fortnightly were not statistically different in nicergoline and placebo groups while the platelet antiaggregating activity of nicergoline was confirmed after a three months' treatment. Bleeding time was unaffected. Minor differences in clinical findings were observed in the two groups.
D000074:Acenocoumarol / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004347:Drug Interactions; D004873:Ergolines / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D009530:Nicergoline / Q000627:therapeutic use*; D010974:Platelet Aggregation / Q000187:drug effects
D004873:Ergolines; D000074:Acenocoumarol; D009530:Nicergoline
Wechselwirkung zwischen Aggregationshemmern und Antikoagulantien. Eine Doppelblindstudie bei gleichzeitiger Applikation von Nicergolin und Acenocoumarol.